Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
InVivo Therapeutics is developing a resorbable biomaterial scaffold, the investigational Neuro-Spinal Scaffold,to treat patients with spinal cord injury (SCI). The Neuro-Spinal Scaffold is in clinical trials for acute SCI, and InVivo is also searching for synergistic pipeline expansion opportunities.
ImmunityBio is applying its second-generation human adenovirus 5 vaccine platform, used as part of its orchestrated multi-modal treatment approach to advanced cancer, to prevent COVID-19.
Cancer Genetics, Inc., a global leader in technology-driven drug discovery and preclinical services, delivers custom solutions for biotech and pharma companies worldwide developing advanced therapies in precision medicine.
GTX Medical is developing innovative neuromodulation therapies to reverse paralysis and improve functional recovery in individuals living with spinal cord injury.
Engine Biosciences has developed a multi-layered platform, NetMAPPR, which integrates machine learning and combinatorial CRISPR to decode biological networks, pinpoint crucial units, and design specific therapeutics.
Semi-virtual SELMA Diagnostics is harnessing its SELMA technology to identify changes in circulating DNA taken from blood samples to create diagnostic tests for early cancer detection, diagnosis and treatment.
Accelerating the drug discovery and development process, Bioelectronica has developed Hypercell, a digital biochemistry integrated single-cell identification and sorting system offering superior output.
Engine Biosciences has developed a multi-layered platform, NetMAPPR, which integrates machine learning and combinatorial CRISPR to decode biological networks, pinpoint crucial units, and design specific therapeutics.
Genome engineering company Synthego pioneers agile genome ‘writing’ with a high-throughput CRISPR-based platform to provide innovative solutions for next-generation therapeutics.
Owkin is building a federated research ecosystem that is fueling collaborative research around the world while preserving patient privacy and data security.
TAXIS Pharmaceuticals is developing first-in-class anti-resistance drugs to help re-engage widely prescribed but resistance-prone generic antibiotics to treat patients with multidrug-resistant infections. The company is actively looking to partner its lead assets with pharma and to in-license novel anti-resistance drug candidates for development.
Panorama Medicine has built a combined genomics and advanced computational analysis platform to develop therapies for diseases treatable through transcriptome modulation. The company is looking to partner its therapeutic solutions through licensing options, or to collaborate on custom screening projects.
With its dynamic end-to-end in-house capabilities, Henlius has developed a unique pipeline of cancer and autoimmune drugs, including HLX01, a biosimilar version of MabThera. The company is now exploring the creation of further biosimilars and immuno-oncology combination therapies.
Biotech company Cellatoz Therapeutics is developing innovative cell therapies by applying its proprietary cells, known as A-to-Z cells to multiple therapeutic areas. The company is now looking for partners to develop the therapies further.
Using its proprietary PREDATOR protein engineering platform, Werewolf designs biotherapeutics that are systemically delivered and activated selectively in the tumor microenvironment to recruit a powerful antitumor immune response.
By harvesting stem cells from umbilical cord blood and differentiating them into natural killer cells, Glycostem has developed oNKord, an affordable off-the-shelf cell therapy product indicated for oncology therapies that is ready to ship worldwide within 48hours
Immuno-oncology company Affimed is harnessing the power of innate immunity, with the help of its ROCK (Redirected Optimized Cell Killing) platform to change the lives of patients with cancer
